Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Padmakumar Narayanan"'
Autor:
Martina H. Lundberg Slingsby, Prakrith Vijey, I-Ting Tsai, Harvey Roweth, Genevieve Couldwell, Adrian R. Wilkie, Hans Gaus, Jazana M. Goolsby, Ross Okazaki, Brooke E. Terkovich, John W. Semple, Jonathan N. Thon, Scott P. Henry, Padmakumar Narayanan, Joseph E. Italiano Jr.
Publikováno v:
Haematologica, Vol 107, Iss 2 (2021)
Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (b
Externí odkaz:
https://doaj.org/article/ac735069e61e406db2676efc4ab4c007
Autor:
Lijiang Shen, Andrea Wong, Satoru Oneda, Brian R. Curtis, Joe Schroeder, Tom Zanardi, Jeffery A. Engelhardt, Scott P. Henry, Padmakumar Narayanan
Publikováno v:
Nucleic Acid Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9cc0b95e2ca1c878d5971a242544cf0
https://doi.org/10.1089/nat.2022.0042
https://doi.org/10.1089/nat.2022.0042
Autor:
Eugene Schneider, Li-Jung Tai, Sebastien A. Burel, Padmakumar Narayanan, Joseph A. Tami, Lijiang Shen, Joseph L. Witztum, T. Jesse Kwoh, Scott P. Henry, Suzanne Paz, Brett P. Monia, Steven G. Hughes, Jeffery A Engelhardt, Sanford J. Shattil, Shuting Xia, Todd Machemer, Brian R. Curtis
Publikováno v:
Nucleic Acid Therapeutics. 30:94-103
Inotersen, a 2'-O-methoxyethyl (2'-MOE) phosphorothioate antisense oligonucleotide, reduced disease progression and improved quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in the NEURO-TTR and NEU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3ffffb1daa283b051e7ec72a1e47a2
https://doi.org/10.1089/nat.2019.0829
https://doi.org/10.1089/nat.2019.0829
Publikováno v:
Current Opinion in Toxicology. 17:41-49
Platelets are small, anuclear, cellular components of blood with a primary role in hemostasis but emerging roles in tissue homeostasis, immunity and disease. Established clinical evaluations of platelets monitor and characterize certain risks of plat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbdcd8ff47834930d7fb1deb69470940
https://doi.org/10.1016/j.cotox.2019.11.001
https://doi.org/10.1016/j.cotox.2019.11.001
Autor:
Beatrice DeBrosse-Serra, Frank Rigo, Holly B. Kordasiewicz, Jamie Watson, Padmakumar Narayanan, Eric E. Swayze, John B. Matson, Curt Mazur, Paymaan Jafar-Nejad, Hien T Zhao, Daniel A. Norris, Armand Soriano, Berit Powers
Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cfd76591a3284de2a841396c6dee028
https://doi.org/10.1101/2020.07.31.216721
https://doi.org/10.1101/2020.07.31.216721
Autor:
Harvey G. Roweth, Padmakumar Narayanan, Martina H. Lundberg Slingsby, I-Ting Tsai, Genevieve Couldwell, Ross Okazaki, Scott P. Henry, Hans Gaus, Brooke E. Terkovich, Adrian R. Wilkie, Jazana M. Goolsby, Prakrith Vijey, Joseph E. Italiano, Jonathan N. Thon, John W. Semple
Publikováno v:
Haematologica. 107(2)
Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2’MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e49177cdc23da840313ce690eb6eba83
https://pubmed.ncbi.nlm.nih.gov/33567808
https://pubmed.ncbi.nlm.nih.gov/33567808
Autor:
Fangli Zhou, Lijiang Shen, Jayne L Schaubhut, Jeffrey A Engelhardt, Bryan Christian, Shipra Gupta, Brian R. Curtis, Sarah Greenlee, Christine Hoffmaster, Joe L Witztum, Mario A Bourdon, Sebastien A. Burel, Scott P. Henry, Padmakumar Narayanan, John P Nolan
Publikováno v:
Toxicological Sciences. 164:613-626
ISIS 104838, a 2'-O-methoxyethyl (2'-MOE)-modified antisense oligonucleotide (ASO), causes a moderate, reproducible, dose-dependent, but selflimiting decrease in platelet (PLT) counts in monkeys and humans. To determine the etiology of PLT decrease i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2da03b9b15092907f4d81dda614661
https://doi.org/10.1093/toxsci/kfy119
https://doi.org/10.1093/toxsci/kfy119
Autor:
Leila Noetzli, Joseph E. Italiano, Scott P. Henry, Brooke E. Terkovich, Jonathan N. Thon, Prakrith Vijey, Padmakumar Narayanan, Genevieve Couldwell, Martina H. Lundberg Slingsby, Ross Okazaki
Publikováno v:
Blood. 132:3747-3747
Introduction Antisense oligonucleotides (ASOs) are a new class of single-stranded DNA based drugs that hold great therapeutic promise for their disease modifying potential in a wide range of genetic diseases. Preclinical toxicology studies in monkeys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47103f0428a09a107d83aeaecc8fe4d7
https://doi.org/10.1182/blood-2018-99-116590
https://doi.org/10.1182/blood-2018-99-116590